Jan. 14, 2013
-- Nemucore Medical Innovations’
(NMI) Co-Founder and Chair of its Scientific Advisory Board, Dr. Vladimir Torchilin, has been named the recipient of the Journal of Drug Targeting’s Lifetime Achievement Award for 2012. This annual award is given by the journal's editorial board and publishers to a scientist who has made exceptional, and sustained contributions to drug delivery and targeting. Dr. Torchilin has made seminal contributions in the area of multifunctional pharmaceutical nanocarriers, mainly liposomes and polymeric micelles, for targeted delivery of imaging agents, drugs, and genes in cancer and cardiovascular diseases. His work has been essential in the formation and continued development of NMI’s innovative nanomedicine products. “The entire NMI team would like to congratulate Dr. Torchilin on this extraordinary award and continued contributions to his field” said Timothy Coleman, NMI’s CEO and President. Dr. Torchilin is currently the Distinguished Professor and Director of Northeastern University’s Center for Pharmaceutical Sciences.
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is dedicated to designing, investigating, developing, and commercializing life-saving nanomedicines for the treatment of ovarian cancer. Ultimately, we believe our products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester and Wellesley, Massachusetts. For more information, please visit http://www.nemucore.com